More data/evidence/long-term 17 6 2 monitoring needed Substitution by the pharmacist should 14 5 - not be allowed More information/education/marketing 8 9 4 needed Immunogenicity concerns 7 - - Concerns about adverse health 6 7 2 outcomes/variances in efficacy General positive comments - good 6 4 5 idea/see value/etc. Cost effective/will reduce costs 5 - - Cost benefits must be matched by 4 3 2 patient interests Stabilised/consistent therapies 2 1 5 important Support as long as 2 3 1 regulations/restrictions in place Confusing for patients 1 3 - Increase/ensure availability 1 - 1 Would consider for new patients only 1 - - Concerns about practitioner resistance - - 4 Other 4 5 3 No comments 38 61 73 Q19. Do you have any specific additional comments that you would like to make about biosimilar medicines? OPEN ENDED
More data/evidence/long-term monitoring needed 17 6 2 Substitution by the pharmacist should not be allowed 14 5 - More information/education/marketing needed 8 9 4 Immunogenicity concerns 7 - - Concerns about adverse health outcomes/variances in efficacy 6 7 2 General positive comments - good idea/see value/etc. 6 4 5 Cost effective/will reduce costs 5 - - Cost benefits must be matched by patient interests 4 3 2 Stabilised/consistent therapies important 2 1 5 Support as long as regulations/restrictions in place 2 3 1 Confusing for patients 1 3 - Increase/ensure availability 1 - 1 Would consider for new patients only 1 - - Concerns about practitioner resistance - - 4 Other 4 5 3 No comments 38 61 73 Q19. Do you have any specific additional comments that you would like to make about biosimilar medicines? OPEN ENDED